Cantos Ventures

Cantos Ventures is a venture capital firm that invests in early-stage biotechnology companies focused on therapeutics, diagnostics, and research tools. The firm targets opportunities in oncology, immunology, neuroscience, and genetic medicines, providing seed and Series A funding. Its portfolio includes companies like Ascentage Pharma, which develops cancer therapies, and Maze Therapeutics, working on kidney disease genetics. Cantos manages over $500 million across multiple funds and has backed more than 40 companies since inception in 2017. Partners have prior experience from Bristol-Myers Squibb and other pharma firms. The firm operates from offices in San Francisco and New York.